Introduction
============

Cancer is the most prevalent cause of death in Korea, despite recent advances in anti-cancer therapy. Currently, death is usually processed within the medical care delivery system, while the distinction between life and death has been obscured by advanced medical technology \[[@b1-crt-2016-446]\]. Thus, discussions and decisions on medical care, including hospice and palliative care (HPC) during the end-of-life (EOL) period, have become more important \[[@b2-crt-2016-446],[@b3-crt-2016-446]\]. Dying is an extremely private experience that varies from person to person \[[@b4-crt-2016-446]\]. Therefore, it is important to consider each patient's personal values and wishes for EOL care. To advocate the patients' wishes and to allow self-determination for EOL care, the use of the advance directives (AD) and physician's order of life-sustaining-treatment (POLST) have been recommended in western countries, and these are included in the Life-Sustaining-Treatment Decision-making Act for dying and hospice/palliative care patients (LST Decision Act), which will be enforced shortly in Korea. The LST Decision Act specifies the physician's explanation about EOL treatment options, including LST and hospice care, and about POLST in the context of advance care planning (ACP). During the ACP process, patients who are near their EOL, including terminal cancer patients, can get the opportunity to discuss their wishes for future healthcare decisions with all stakeholders, including physicians, family members, and/or others \[[@b5-crt-2016-446]\]. The product of this process is either AD or POLST, and the key factor for making decisions considering the patient's best interest is communication among the stakeholders during this type of discussion \[[@b6-crt-2016-446]\].

Given that EOL discussions will become more important in Korea along with the implementation of the LST Decision Act, studies to identify clinical situations and/or strategies to facilitate this type of discussion are needed, as these are currently lacking. Therefore, this study was performed to explore the issues or problems hindering EOL discussions and to suggest strategies for better EOL discussions. To this end, this study aimed to (1) identify the patterns and barriers that oncologists and resident physicians have experienced in EOL discussions in current clinical circumstances and (2) solicit their opinions about better EOL discussions, particularly in terms of the facilitators needed in such discussions.

Materials and Methods
=====================

Oncologists and resident physicians who treated cancer patients during the study period were invited to participate in this survey. The survey was performed from June 2013 to January 2014 using a questionnaire. The study questionnaire was developed by the authors to explore the oncologists' and residents' experiences and opinions on EOL discussion. To develop the questionnaire, query items were generated by the authors, and the content validity of the generated items was subsequently verified through an expert review process. The draft questionnaires were polished to obtain a final version of the questionnaire after a pilot test with a sample of five oncologists and five residents. The final questionnaires were distributed to the eligible subjects by two methods: directly administered at the 2013 annual symposium of the Korean Cancer Association for oncologists and mailed to oncologists who had agreed to distribute the questionnaires to the resident physicians in their affiliated institutions.

The characteristics of each group of respondents are presented using descriptive statistics. Differences in EOL discussion experiences and opinions for better discussion between the oncologists and residents were examined using the t test or chi-square test, as appropriate.

Results
=======

1. Subject characteristics
--------------------------

A total of 379 participants agreed to participate in this study. Of these, three respondents were excluded due to incomplete responses. Hence, the final sample consisted of 376 physicians, including 147 oncologists and 229 residents. The demographic characteristics of the respondents are presented in [Table 1](#t1-crt-2016-446){ref-type="table"}. As expected, the oncologist group was older, contained a higher proportion of married individuals, and showed a higher education level. More oncologists were also religious, while the affiliations were similar between the two groups.

2. Experience in EOL discussion
-------------------------------

Approximately two-thirds of the oncologists (64.4%) and residents (61.7%) referred to "terminal stage" as a life expectancy of either less than 6 months or less than 2-3 months. In both groups, almost all respondents tried to disclose the bad news to the patients and/or their family members ([Table 2](#t2-crt-2016-446){ref-type="table"}). The two groups showed a significant difference regarding the timing to initiate EOL discussion (p \< 0.001). The oncologists reported that they usually began EOL discussion when chemotherapy was expected to be discontinued, while the residents most frequently did so when the life expectancy was less than 6 months. Both groups reported that oncologists were the ones who usually initiated EOL discussions in their clinical practice. Both groups reported that the patients and family members were the major discussion participants. However, a difference in the discussion participants was observed between the two groups as well, with a significantly larger proportion of residents discussing the EOL care with the family members only, in the absence of the patients. In terms of the discussion topics, disease trajectory issues, including the progress and prognosis of disease (92.82%), and the possibility of recovery (82.71%) were the most frequent topics. As for EOL care options, cardiopulmonary resuscitation (CPR; 77.13%), HPC (73.40%), LST (71.54%), and the place of EOL care (58.51%) were the four most common subjects discussed. Relatively low proportions of respondents reported that they discussed the benefits and burden of chemotherapy (37.23%) and any alternative treatments (23.14%). Interestingly, proxy appointments were also discussed by a small proportion of respondents (22.07%). The difficulty in life expectancy estimation was explored as the major barrier for residents (61.14%), whereas family members' reluctance to include the patient in the discussion was the most common barrier (55.78%) for oncologists ([Table 2](#t2-crt-2016-446){ref-type="table"}).

The average number of cases per month that involved EOL discussions was 6.24, and the number of patients that were transferred to HPC significantly differed between the groups, with more HPC transfers occurring in the oncologist group than in the resident group. Overall, the level of satisfaction regarding the EOL discussion practiced in each respondent's institution was reported to be rather low (57.82 of 100).

3. Opinions for better EOL discussion process
---------------------------------------------

Discontinuation of chemotherapy and exacerbation of disease such as metastasis or recurrence of disease were suggested as the two most significant indications to begin EOL discussion by both oncologists and residents ([Table 3](#t3-crt-2016-446){ref-type="table"}). The majority of respondents (83.33%) considered oncologists as the most appropriate persons to initiate the EOL discussion. Regardless of the groups, hospice care specialists (41.10%) were suggested as the best expert for conducting ongoing EOL discussions. However, there were significant differences in the opinion about the other qualified experts for ongoing EOL discussions between the two groups; more oncologists (35.71%) considered palliative coordinators as adequate personnel to continue the discussion, compared to in the resident group (21.78%), whereas more residents (35.56%) than oncologists (21.43%) believed that oncologists were the most appropriate personnel for ongoing discussions. Most study respondents reported that both the patients and their family members should be included in the discussion together. Furthermore, CPR (95.74%), mechanical ventilation (89.63%), and hemodialysis (64.36%) were the treatment options discussed for EOL care by most respondents. The respondents reported the patients' wishes or values toward EOL care as the most important factor to be considered in the decision of LST ([Table 3](#t3-crt-2016-446){ref-type="table"}).

4. Barriers and facilitators
----------------------------

The most prevalently recognized barriers for EOL discussion were the family's reluctance to include a patient in the discussion (55.78%) and prognostication difficulty (61.14%) in the oncologist and resident groups, respectively. Family members' request for continuation of treatment (42.29%), conflict among family members (39.89%), concerns about disappointment or hopelessness of the patient (38.30%), time constraints (22.07%), and fear of death or feelings of guilt (21.54%) were also reported as barriers across all respondents. In a minor proportion, practical issues, including legal and communicational issues, were mentioned as well ([Table 4](#t4-crt-2016-446){ref-type="table"}).

Both groups considered knowledge or understanding about prognostication (67.54%) and the patients' and their family members' socio-psychosocial status (56.38%) as the major facilitating factors for EOL discussions ([Table 4](#t4-crt-2016-446){ref-type="table"}). Knowledge (35.37%) and experience (31.12%) in terms of the treatment options and hospice care, communication skills (29.52%), palliative care team (24.20%), conflict resolution skills (19.15%), knowledge about legal and ethical issues (15.16%), payment for counseling services (14.89%), and coping skills for psychological distress (8.78%) were also claimed as facilitating factors ([Table 4](#t4-crt-2016-446){ref-type="table"}).

Discussion
==========

This study aimed to investigate the clinical practice of EOL discussions, especially for terminal cancer patients, and the professional opinions on how to ensure better EOL discussions and what the major barriers and facilitators were conceived to be.

The oncologists and resident physicians reported various definitions of "terminal state" in the present study, suggesting that the terminal state is diversely interpreted by healthcare professionals, similar to what was reported in a previous study \[[@b7-crt-2016-446]\]. In more than half of the study respondents, the terminal state was regarded as a life expectancy of less than 6 months or less than 2-3 months by both the oncologists and residents. These results seem relevant considering the facts that the terminal state is defined as a life expectancy of 6 months or less in the U.S. Medicare policy \[[@b8-crt-2016-446]\] and that the LST Decision Act defines the terminal state as the state in which impending death might occur within a few months. However, in a previous study, concerns about the definition of "terminal state" based on a specific period of life expectancy were raised, and the necessity of taking the whole context into consideration was emphasized \[[@b9-crt-2016-446]\]. The American Cancer Society also defined the terminal state more broadly, without referring to life expectancy \[[@b10-crt-2016-446]\]. In addition, uncertainty about the illness trajectory has been recognized as an important barrier for discussing EOL care \[[@b11-crt-2016-446]\]. Therefore, a more comprehensive definition of terminal state would be desirable, and a disease-based definition has recently been proposed in the enforcement regulation of the LST Decision Act.

The diverse definitions could influence the communication between the physicians and patients, as well as among healthcare providers. According to a study on whether the same language was used for communication between healthcare professionals and the general population \[[@b12-crt-2016-446]\], 74.5% of adults referred to \"advanced breast cancer with lung metastasis\" as a \"terminal\" illness, which was different from the medical opinion. This finding suggests that efforts should be made to narrow the gap in the understanding of the relevant terms, including "terminal state" between healthcare professionals and the general population \[[@b12-crt-2016-446]\], aside from establishing consensus among healthcare providers for clearer EOL discussion. In addition, the LST Decision Act distinguishes the terms "terminal state" and "dying phase" and specifies each definition respectively. Putting aside controversies regarding the statements of the Act, healthcare providers need to practice the law, and oncologists and residents need to acknowledge the lawful definitions and diagnostic criteria for the terminal state and dying phase of cancer patients.

In the present study, the oncologists and residents showed a significant difference in the timing for EOL discussion, with various times emerging. Most residents initiated EOL discussions when the life expectancy was expected to be less than 6 or 2-3 months, while the oncologists did so around the time cancer treatment was interrupted, especially when chemotherapy was expected to be discontinued. Interestingly, similar to in the oncologist group, the resident group suggested the best timing to initiate EOL discussion as when withdrawal of chemotherapy was expected and the disease state deteriorated, that is, the residents did not practice what they preached. However, explaining the gap between opinions and practice among residents is beyond the scope of this study, and efforts should be made to narrow the gap in practice in the future. Nevertheless, the diverse practices and opinions about the discussion timing in this study not only reflect how difficult it is to suggest any concrete process for EOL discussion, but also support the notion that it is important to consider the whole context in EOL discussion \[[@b13-crt-2016-446]\].

Furthermore, almost all respondents tried to inform the patient and/or their family members of the patient's condition. This result is quite encouraging and differs from that of a previous study in which the physicians preferred to avoid this type of communication \[[@b14-crt-2016-446]\]. Noteworthy, more residents (44.3%) than oncologists (22.7%) discussed the EOL care only with the family members. This finding has great implications in two aspects: first, it has been well recognized that patients are usually excluded from EOL discussions in Korea. Second, only patients can make decisions for their own EOL care via AD or POLST under the LST Decision Act. In these regards, more emphasis needs to be placed on the importance of patient participation in EOL discussions, particularly for resident physicians. On the contrary, most study respondents argued that both patients and their family members should be involved in EOL discussions. Therefore, means to support them to practice what they preach will be necessary.

From the results of the questionnaire on the clinical experience with terminal cancer patients, more oncologists than residents reported that they transferred patients to HPC, and this result was similar to that of a previous study \[[@b13-crt-2016-446]\]. Timely transfer to HPC has been argued to allow the patients and their family better outcomes and quality of life in a complex landscape of cancer treatment \[[@b15-crt-2016-446]\]. Such being the case, early palliative care referral concurrent with active treatment was recommended in a previous study \[[@b16-crt-2016-446]\]. Therefore, strategies to encourage timely referral to HPC, especially for resident physicians, need to be identified and practiced.

Both the oncologists and residents referred to oncologists and palliative care specialists as the most appropriate experts for EOL discussion initiation and ongoing communication, respectively. Actually, in clinical practice, cancer patients and their family members usually rely on oncologists, who order treatments and provide medical information to them. However, oncologists are generally restricted in time for such ongoing and time-consuming communication; thus, an HPC team approach might be a feasible alternative for ongoing EOL discussions. In the current clinical setting, the residents also host EOL discussions and transfer patients to HPC services, although significantly less frequently than oncologists. Therefore, education, training, and supporting systems particularly designed for resident physicians are called for.

More than half of the study respondents suggested CPR, mechanical ventilation, and hemodialysis as treatment options to be mentioned in the EOL discussion. This is similar to the results of previous studies \[[@b7-crt-2016-446],[@b17-crt-2016-446]\]. Moreover, these three treatment options are listed as life-sustaining treatments in the LST Decision Act, along with chemotherapy. In addition, artificial nutrition/hydration, blood transfusion, and antibiotics were also suggested as EOL care options to be discussed, albeit by relatively low proportions of respondents. Different attitudes toward artificial nutrition/hydration were also noted between the oncologists and residents, with the residents considering the necessity of decision-making regarding this procedure as low. According to a previous study \[[@b7-crt-2016-446]\], more than 70% of patients, caregivers, and adults considered discussion of this treatment as necessary. These different perspectives among healthcare providers, patients, and caregivers may cause conflicts in the decision-making and mutual understanding. Furthermore, this option is not included in the LST Decision Act, which is different from in other countries, including in the United States. Thus, caution should be practiced while healthcare providers communicate treatment options not listed in the Act, even though they believe that those treatment options deserve to be discussed, as long as the law is valid.

In the present study, almost all respondents tried to communicate bad news to the patient and/or family members, and revealed a rather low satisfaction level (57.82/100) regarding the current EOL discussion process. This low satisfaction level might be interrelated with the barriers and facilitators reported herein, which could be categorized into two major issues, namely knowledge (medical, legal, and ethical) and communication (skills and policies) issues. These two issues are key components of various EOL care guidelines \[[@b18-crt-2016-446]-[@b20-crt-2016-446]\] and require prompt attention since the LST Decision Act is expected to be increasingly practiced in the near future in Korea and since more oncologists and/or residents are expected to be involved in EOL discussions, whether they are prepared for it or not.

These two issues of knowledge and communication need to be discussed further since they are such critical aspects in EOL discussion. First, as for knowledge, prognosis estimation was both the major barrier and facilitator and was also identified as the main subject of EOL discussion in current practice. Therefore, prognostication issues need to be recognized as the most important topic in EOL discussion. Accurate prognosis estimation is especially important because it can ensure adequate EOL care decision-making, including timely HPC transfer. Accordingly, knowledge for prognostication should be considered the most important and urgent issue in preparing physicians for the EOL discussion process. Diverse prognostic models have been introduced for more accurate survival prediction, and one model for terminal cancer patients was validated in Korea, with higher effectiveness than doctors' estimation \[[@b21-crt-2016-446]\]. More unified and validated tools for specific illnesses are required to aid the healthcare providers in this matter.

Another aspect that requires attention is the discussion about the benefits/burdens of chemotherapy, which was found to be suboptimal in this study. The benefit/burden of each treatment is known to represent essential information for EOL discussion \[[@b18-crt-2016-446]\] and should not be overlooked. Accurate medical information could allow the patients and family members to make proper decisions, and issues related to the benefit/burden of treatment are also considered important, along with prognostic information. Furthermore, knowledge or experience of diverse treatments, hospice care, and legal and ethical aspects was also recognized as important aspects for better EOL discussion by the study respondents, and the design of education and training modules including these subjects would be helpful.

In this study, the family members' reluctance to include the patient in the discussion, family conflicts, psychosocial aspects such as hopelessness, and even the communication skills of the physician emerged as both barriers and facilitators. These matters are all associated with communication. The underpinning philosophy of the LST Decision Act is patient autonomy and choice, and this philosophy could be supported through the ongoing process of ACP, which is now viewed as an intrinsic component of the EOL care program \[[@b22-crt-2016-446]\]. The concept of ACP has become broader \[[@b22-crt-2016-446]\], and communication is critical for effective EOL discussion in the context of ACP \[[@b18-crt-2016-446]\]. Therefore, practical and case-based communication guidelines or manuals need to be developed for healthcare providers.

Furthermore, while communicating with patients and their family members, healthcare providers need to consider cultural aspect, because all human decisions are closely related to culture \[[@b23-crt-2016-446]\], and EOL discussions should hence be performed in a cultural context \[[@b23-crt-2016-446],[@b24-crt-2016-446]\]. Thereby, EOL discussion guidelines that correspond to Korean culture are required. In this regard, a previous study \[[@b12-crt-2016-446]\] proposed that the decision-making dynamics surrounding the patient needs to be taken into account for proper discussion.

Interestingly, in the present study, some respondents claimed their fears of death and/or feelings of guilt as barriers, indicating that the psychological aspect of the terminal care providers also is important. In the National Comprehensive Cancer Network guidelines \[[@b21-crt-2016-446]\], psychosocial support for palliative care providers after they lost a patient is included. Thus, in future EOL care guidelines in Korea, psychosocial support for the care providers, during as well as after the care, should be considered.

Efforts to support self-determination, as described in the LST Decision Act, in discussing EOL care may not be always successful, considering the present study results of family members' reluctance to discuss the EOL care with their loved ones, evidence suggesting that not all patients want an active role in making the decisions \[[@b14-crt-2016-446]\], and that the preparation rate of AD in the United States is low \[[@b25-crt-2016-446]\]. If so, efforts should be made to facilitate EOL discussions in a larger framework and to allow healthcare professionals to flexibly cope with individual matters. In this context, the present study proposes that the EOL discussion should be concentrated on the process, rather than on documentation itself, and that AD or POLST should be considered as both the vehicle and product of the discussion. Accordingly, there is no doubt that EOL discussion is critical to ensure better quality of life for the last months and days of the patient. Again, it is indispensable for healthcare professionals not only to have medical expertise, but also to communicate effectively by considering the patients' and their family members' psychological needs. Thus, the importance of knowledge and communication skills is obvious and cannot be emphasized enough to facilitate EOL discussions. Education and training for each target group, such as oncologists or resident physicians, need to be developed in the two dimensions of knowledge and communication, and social marketing would also be required to improve the stakeholder engagement.

In conclusion, this study revealed various perspectives of oncologists and resident physicians about EOL discussion in terms of the definition of terminal stage, clinical experience of EOL discussion, and opinions for better EOL discussion. The study respondents considered that knowledge of the medical, legal, and ethical aspects and communicational preparation were essential to deal with awkward situations of EOL care discussion process. The present study suggests that efforts should be made to educate and train healthcare providers who are engaged in EOL discussion, considering that the LST Decision Act will soon be implemented.
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###### 

General characteristics of respondents

  Variable                 Total (n=376)   Oncologist (n=147)   Resident (n=229)
  ------------------------ --------------- -------------------- ------------------
  **Sex**                                                       
   Male                    225 (59.84)     78 (53.1)            147 (64.19)
   Female                  151 (40.16)     69 (46.9)            82 (35.81)
  **Age (yr)**             33.43±7.13      39.26±7.72           29.68±2.99
  **Marital state**                                             
   Single                  179 (47.61)     38 (25.85)           141 (61.57)
   Married                 195 (51.86)     107 (72.79)          88 (38.43)
   Widowed                 1 (0.27)        1 (0.68)             0
   Divorced                1 (0.27)        1 (0.68)             0
  **Education (degree)**                                        
   Bachelor                226 (60.11)     30 (20.41)           196 (85.59)
   Master                  87 (23.14)      56 (38.10)           31 (13.54)
   Doctoral                63 (16.76)      61 (41.50)           2 (0.87)
  **Religion**                                                  
   None                    179 (47.61)     50 (34.01)           129 (56.33)
   Protestant              108 (28.82)     55 (37.41)           53 (23.14)
   Catholic                60 (15.96)      33 (22.45)           27 (11.79)
   Buddhist                29 (7.71)       9 (6.12)             20 (8.73)
  **Affiliation**                                               
   GH                      281 (74.73)     108 (73.47)          173 (75.55)
   Intermediate GH         88 (23.40)      34 (23.13)           54 (23.58)
   Clinic                  7 (1.86)        5 (3.40)             2 (0.87)

Values are presented as number (%) or mean±standard deviation. GH, general hospital.

###### 

Experience in end-of-life discussion

  EOL discussion                                                                        Total (n=367)   Oncologist (n=147)   Resident (n=229)   p-value
  ------------------------------------------------------------------------------------- --------------- -------------------- ------------------ ----------
  **Definition of terminal state^[a)](#tfn1-crt-2016-446){ref-type="table-fn"}^**                                                               
   Life expectancy 6 months or less                                                     127 (34.05)     50 (34.25)           77 (33.92)         0.563
   Life expectancy 2-3 months                                                           107 (28.69)     44 (30.14)           63 (27.75)         
   Deterioration of condition                                                           77 (20.64)      24 (16.43)           53 (23.35)         
   Discontinuation of chemotherapy                                                      49 (13.34)      23 (15.75)           26 (11.45)         
   Impending death                                                                      2 (0.54)        0                    2 (0.88)           
   Others                                                                               11 (2.95)       5 (3.42)             6 (2.64)           
  **Timing to initiate discussion^[a)](#tfn1-crt-2016-446){ref-type="table-fn"}^**                                                              
   Life expectancy 2-3 months or less                                                   75 (20.16)      31 (21.68)           44 (19.21)         \< 0.001
   When chemotherapy is expected to be discontinued                                     74 (19.89)      36 (25.17)           38 (16.59)         
   Life expectancy 6 months or less                                                     73 (19.62)      21 (14.69)           52 (22.70)         
   Upon chemotherapy discontinuation                                                    63 (16.94)      34 (23.78)           29 (12.66)         
   Upon metastasis or recurrence                                                        48 (12.90)      14 (9.79)            34 (14.85)         
   Impending death                                                                      21 (5.65)       1 (0.70)             20 (8.73)          
   Upon cancer diagnosis                                                                15 (4.03)       3 (2.10)             12 (5.24)          
   Others                                                                               3 (0.81)        3 (2.10)             0                  
  **Notification bad news**                                                                                                                     
   Always notify                                                                        247 (65.69)     103 (70.07)          144 (62.88)        0.327
   Notify as much as possible                                                           128 (34.04)     44 (29.93)           84 (36.68)         
   Not notify as possible                                                               1 (0.27)        0                    1 (0.44)           
   Others                                                                               10 (2.77)       2 (1.45)             8 (3.59)           
  **Discuss with^[a)](#tfn1-crt-2016-446){ref-type="table-fn"}^**                                                                               
   Patients and family members                                                          234 (62.73)     109 (75.17)          125 (54.82)        \< 0.001
   Family members                                                                       133 (35.66)     32 (22.07)           101 (44.30)        
   Patients                                                                             6 (1.61)        4 (2.76)             2 (0.88)           
  **Discussion subjects^[b)](#tfn2-crt-2016-446){ref-type="table-fn"}^**                                                                        
   Prognosis                                                                            349 (92.82)     135 (91.84)          213 (93.01)        
   Cardiopulmonary resuscitation                                                        291 (77.13)     99 (67.35)           191 (83.41)        
   Hospice/Palliative care                                                              276 (73.40)     113 (76.87)          164 (71.62)        
   Life-sustaining treatments                                                           269 (71.54)     95 (64.63)           173 (59.83)        
   Place of EOL care                                                                    220 (58.51)     85 (57.82)           134 (58.52)        
   Benefits and burden of chemotherapy                                                  140 (37.23)     49 (33.33)           89 (38.86)         
   Alternative treatments                                                               87 (23.14)      49 (33.33)           38 (16.59)         
   Proxy appointment                                                                    83 (22.07)      30 (20.41)           53 (23.14)         
  **Hospice palliative care transfer^[a)](#tfn1-crt-2016-446){ref-type="table-fn"}^**                                                           
   1-2 times/mo                                                                         155 (42.12)     43 (30.50)           112 (49.34)        \< 0.001
   3-5 times/mo                                                                         110 (29.89)     35 (24.82)           75 (33.04)         
   None                                                                                 45 (12.22)      24 (17.02)           21 (9.25)          
   6-10 times/mo                                                                        30 (8.15)       18 (12.77)           12 (5.29)          
   ≥ 10 times/mo                                                                        28 (7.61)       21 (14.89)           7 (3.08)           
  **No. of EOL discussion per month**                                                   6.24±9.10       7.60±11.96           5.44±6.65          0.031
  **Level of satisfaction about EOL discussion**                                        57.82±17.39     57.85±17.58          57.69±17.35        0.935

Values are presented as number (%) or mean±standard deviation.

Missing data excluded from analysis,

Multiple response.

###### 

Opinions for better end-of-life discussion

  EOL discussion                                                                                  Total (n=367)   Oncologist (n=147)   Resident (n=229)   p-value
  ----------------------------------------------------------------------------------------------- --------------- -------------------- ------------------ ---------
  **Timing to initiate discussion^[a)](#tfn3-crt-2016-446){ref-type="table-fn"}^**                                                                        
   When chemotherapy discontinuation is expected                                                  112 (30.03)     48 (32.88)           64 (29.96)         0.117
   Upon metastasis or recurrence                                                                  108 (28.95)     52 (35.62)           56 (24.67)         
   Upon diagnosis of cancer                                                                       73 (19.57)      22 (15.07)           51 (22.47)         
   Upon chemotherapy discontinuation                                                              56 (15.01)      17 (11.64)           39 (17.18)         
   When one is healthy                                                                            16 (4.29)       4 (2.74)             12 (5.29)          
   Impending death                                                                                4 (1.07)        1 (0.68)             3 (1.32)           
   Others                                                                                         4 (1.07)        2 (1.37)             2 (0.88)           
  **Discussion initiated by^[a)](#tfn3-crt-2016-446){ref-type="table-fn"}^**                                                                              
   Oncologists                                                                                    305 (83.33)     121 (84.61)          184 (82.51)        0.772
   Hospice care specialist                                                                        44 (12.02)      14 (9.79)            30 (13.45)         
   Palliative care coordinator                                                                    11 (3.01)       5 (3.50)             6 (2.69)           
   Others                                                                                         6 (0.44)        3 (2.10)             3 (1.35)           
  **Ongoing discussion by^[a)](#tfn3-crt-2016-446){ref-type="table-fn"}^**                                                                                
   Hospice care specialist                                                                        150 (41.10)     57 (40.71)           93 (41.33)         0.035
   Oncologists                                                                                    110 (30.14)     30 (21.43)           80 (35.56)         
   Palliative care coordinator                                                                    99 (27.12)      50 (35.71)           49 (21.78)         
   Chaplaincy                                                                                     2 (0.55)        1 (0.71)             1 (0.44)           
   Others                                                                                         4 (1.10)        2 (1.43)             2 (1.89)           
  **Discuss with^[a)](#tfn3-crt-2016-446){ref-type="table-fn"}^**                                                                                         
   Patients and families                                                                          318 (85.24)     127 (87.00)          191 (84.14)        0.781
   Patients                                                                                       31 (8.31)       11 (7.53)            20 (8.81)          
   Families                                                                                       23 (6.17)       8 (5.48)             15 (6.61)          
   Others                                                                                         1 (0.27)        0                    1 (0.44)           
  **Treatment options included in discussion^[b)](#tfn4-crt-2016-446){ref-type="table-fn"}^**                                                             
   Cardiopulmonary resuscitation                                                                  360 (95.74)     137 (93.20)          223 (97.38)        
   Mechanical ventilation                                                                         337 (89.63)     131 (89.12)          206 (89.96)        
   Hemodialysis                                                                                   242 (64.36)     101 (68.71)          141 (61.57)        
   Artificial nutrition/Hydration                                                                 135 (35.90)     72 (49.00)           63 (27.51)         
   Blood transfusion                                                                              91 (24.20)      43 (29.25)           48 (20.96)         
   Antibiotics                                                                                    63 (16.76)      31 (21.09)           32 (13.97)         
  **Factors considered for LST decision making^[a)](#tfn3-crt-2016-446){ref-type="table-fn"}^**                                                           
   Patient's wishes or values                                                                     194 (54.19)     73 (52.52)           121 (55.25)        0.743
   Family's opinions                                                                              79 (22.07)      28 (20.14)           51 (23.29)         
   Physician's opinions                                                                           65 (18.16)      29 (20.86)           36 (16.44)         
   Opinions of proxy                                                                              17 (4.75)       7 (5.04)             10 (4.57)          
   Others                                                                                         3 (0.84)        2 (1.44)             1 (0.46)           

EOL, end-of-life; LST, life sustaining treatment.

Missing data excluded from analysis,

Multiple response.

###### 

Barriers and facilitators of end-of-life discussion

  Category                                                                    Total (n=376)   Oncologist (n=147)   Resident (n=229)
  --------------------------------------------------------------------------- --------------- -------------------- ------------------
  **Barriers^[a)](#tfn5-crt-2016-446){ref-type="table-fn"}^**                                                      
   Prognostication difficulty                                                 213 (56.65)     71 (48.30)           140 (61.14)
   Family's reluctance to include a patient in discussion                     175 (46.54)     82 (55.78)           92 (40.17)
   Family's request for continuation of treatment                             159 (42.29)     56 (38.10)           103 (44.98)
   Conflict among family members                                              150 (39.89)     47 (31.97)           101 (44.10)
   Concerns about disappointment or hopelessness                              144 (38.30)     63 (42.86)           81 (35.37)
   Lack of time                                                               83 (22.07)      46 (31.29)           37 (16.16)
   Fear of death or guilty feeling                                            81 (21.54)      27 (18.37)           54 (23.58)
   Probable legal issues                                                      34 (9.04)       7 (4.76)             27 (11.79)
   Lacking in communication skills                                            26 (6.91)       10 (6.80)            15 (6.55)
  **Facilitators^[a)](#tfn5-crt-2016-446){ref-type="table-fn"}^**                                                  
   Knowledge about prognostication                                            254 (67.55)     84 (59.18)           170 (74.24)
   Understanding of patient and family member's socio-psychological aspects   212 (56.38)     86 (58.50)           126 (55.02)
   Knowledge of treatments and hospice care                                   133 (35.37)     50 (34.01)           83 (36.24)
   Experiences of treatments and hospice care                                 117 (31.12)     54 (36.73)           61 (26.64)
   Communication skills                                                       111 (29.52)     53 (36.05)           58 (25.33)
   Constitution of palliative care team                                       91 (24.20)      42 (28.57)           49 (21.40)
   Conflict resolution skills                                                 72 (19.15)      21 (14.29)           51 (22.27)
   Knowledge about legal and ethical issues                                   57 (15.16)      17 (11.56)           40 (17.47)
   Payment for counselling services                                           56 (14.89)      27 (18.37)           29 (12.66)
   Coping skills for psychological distress                                   33 (8.78)       11 (7.48)            22 (9.61)

Values are presented as number (%).

Multiple response.
